Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation

Inhibitors for histone deacetylases (HDACs) have been identified as epigenetic drug targets to treat a variety of malignancies through several molecular mechanisms. The present study is aimed at investigating the mechanism underlying the possible antitumor effect of the HDAC inhibitor chidamide (CDM...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yongpan, Zheng, Jujia, Huo, Qiang, Chen, Zhongchao, Chen, Jun, Xu, Xiangwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816583/
https://www.ncbi.nlm.nih.gov/pubmed/35126526
http://dx.doi.org/10.1155/2022/3632549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816583/
https://www.ncbi.nlm.nih.gov/pubmed/35126526
http://dx.doi.org/10.1155/2022/3632549

Ejemplares similares